Fourth Circuit Halts West Virginia 340B Drug Law
The Fourth Circuit halted West Virginia's 340B law, maintaining current discount practices.
Why it matters: This ruling protects drugmakers from state-imposed mandates, impacting compliance and financial operations.
- Ruling issued on March 31, 2026.
- West Virginia's 340B law required discounts to contract pharmacies.
- Conflict with federal 340B rules raised by manufacturers.
- State law included $50,000 fines for non-compliance.
The U.S. Court of Appeals for the Fourth Circuit ruled on March 31, 2026, against West Virginia's S.B. 325, blocking its enforcement. The law sought to extend 340B drug discounts to contract pharmacies, a mandate now on hold due to the ruling.
Drug manufacturers, including Novartis and AbbVie, argued the state law conflicted with federal regulations by imposing undue compliance burdens. They asserted that S.B. 325 disrupts the federally established structure of the 340B program, a stance the court upheld.
Initially enacted in March 2024, S.B. 325 aimed to prevent drug manufacturers from restricting deliveries to contract pharmacies and included a $50,000 penalty for each non-compliance incident. This posed significant legal and financial risks for drugmakers operating in West Virginia.
The American Hospital Association, via amicus briefs, contended the legislation facilitated aid for low-income patients. Divergent federal circuit court decisions, such as an opposite finding in the Eighth Circuit on an Arkansas law, suggest possible elevation to the U.S. Supreme Court for ultimate resolution. At heart is whether states can impose their own 340B rules beyond the federally controlled framework.
By the numbers:
- 2026 — Year the Fourth Circuit issued the ruling.
- $50,000 — Penalty per incident under West Virginia's 340B law.
Yes, but: Differing federal circuit rulings indicate ongoing uncertainty in 340B regulation enforcement.
What's next: Potential escalation of the 340B state versus federal ruling conflict to the Supreme Court.